BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 3838792)

  • 21. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteonecrosis of sternum and rib in a patient treated for Hodgkin's disease.
    Blijham GH; Vermeulen A; Mendes de Leon DE
    Cancer; 1985 Nov; 56(9):2292-4. PubMed ID: 3840407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hodgkin's disease, splenectomy and secondary leukemia.
    Centurioni R; Brianzoni F; Leoni P; Danieli G
    Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
    [No Abstract]   [Full Text] [Related]  

  • 25. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
    Klimo P; Connors JM
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP; Niedzwiecki D; Johnson JL
    N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract]   [Full Text] [Related]  

  • 27. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 28. The intergroup Hodgkin's disease in children. A study of stages I and II.
    Gehan EA; Sullivan MP; Fuller LM; Johnston J; Kennedy P; Fryer C; Gilchrist GS; Hays DM; Hanson W; Heller R
    Cancer; 1990 Mar; 65(6):1429-37. PubMed ID: 2407336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current management of Hodgkin's disease.
    Behrens BC; Young RC; DeVita VT
    Drugs; 1985 Oct; 30(4):355-67. PubMed ID: 3905335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.
    Cimino G; Biti GP; Anselmo AP; Maurizi Enrici R; Bellesi GP; Bosi A; Cionini L; Mungai V; Papa G; Ponticelli P
    J Clin Oncol; 1989 Jun; 7(6):732-7. PubMed ID: 2715803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute myeloid leukemia after treatment of Hodgkin's disease].
    Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.
    Diehl LF; Perry DJ; Terebelo H; Baldwin PE; Hurwitz M; Kimball DB; Dorn RV
    Cancer Treat Rep; 1983 Sep; 67(9):827-9. PubMed ID: 6883360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.
    Rosenberg SA; Kaplan HS
    Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):5-22. PubMed ID: 3881376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second malignant neoplasm in treated Hodgkin's disease. Report of a patient and scope of the problem.
    Takaue Y; Sullivan MP; Ramirez I; Cleary KR; van Eys J
    Am J Dis Child; 1986 Jan; 140(1):49-51. PubMed ID: 3079944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-Hodgkin lymphoma following Hodgkin's disease. A case report.
    Heinz R; Hanak H
    Blut; 1984 Oct; 49(4):353-7. PubMed ID: 6548395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
    Valagussa P; Bonadonna G
    Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
    [No Abstract]   [Full Text] [Related]  

  • 37. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.